Risk of tardive dyskinesia is influenced by treatment exposure and individual factors. Longer cumulative exposure to dopamine receptor-blocking medicines is relevant, but the condition does not occur in everyone. Age, previous movement effects and other clinical features may also affect risk. Second-generation drugs do not eliminate the possibility.<\/p>\n
Tardive dyskinesia is a movement disorder associated with exposure to dopamine receptor-blocking medicines. It often develops after ongoing treatment, although patterns vary. Movements can persist and may affect function or wellbeing. It differs from acute dystonia, akathisia and drug-induced parkinsonism, making accurate assessment important rather than treating all movement changes as one problem.<\/p>\n
Risk factors describe probabilities rather than a precise forecast. They cannot identify exactly who will develop symptoms or justify ignoring a new movement in someone considered low risk. Assessment also considers other medicines that block dopamine, including some used outside psychiatry. A history of exposure remains important even if the current prescription has changed. Prevention involves thoughtful prescribing, review and monitoring rather than promising a risk-free drug. The person’s need for symptom control must be balanced with awareness of long-term effects through shared clinical decisions.<\/p>\n
Cumulative exposure includes relevant medicines from earlier treatment, not only the current prescription. Some dopamine-blocking agents are used for nausea or other non-psychiatric indications. A complete history can therefore reveal exposure that a psychiatric medication list misses. Risk review should remain individual and avoid suggesting that a low current dose or a newer agent makes screening unnecessary.<\/p>\n
Further reading:<\/strong> National Institute of Mental Health<\/a>; DailyMed prescribing information<\/a>; US FDA medicine information<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":" Risk of tardive dyskinesia is influenced by treatment exposure and individual factors. Longer cumulative exposure to dopamine receptor-blocking medicines is relevant, but the condition does not occur in everyone. Age, previous movement effects and other\u2026Continue Reading<\/a><\/span><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48],"tags":[51],"class_list":["entry","author-","has-excerpt","post-748","post","type-post","status-publish","format-standard","category-medication-effects","tag-tardive-dyskinesia"],"brizy_media":[],"_links":{"self":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/posts\/748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=748"}],"version-history":[{"count":0,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=\/wp\/v2\/posts\/748\/revisions"}],"wp:attachment":[{"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/schizophrenia.world\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}